Digital mental-health provision has moved from a pandemic-era experiment to a fixture of public-sector commissioning on both sides of the Atlantic, and few London-listed companies illustrate that shift as directly as Kooth plc (LSE: KOO).

Kooth's business is built around free, anonymous online counselling and peer-support services commissioned by health systems rather than sold to individual consumers. The central story right now: a business that grew explosively through US public-health contracts, then recorded a revenue and margin pause in 2025 — while still carrying no debt and a reinvestment-first capital policy.

The Quick Version

  • Kooth reported FY2025 revenue of £63.3 million, down from £66.7 million in FY2024, with adjusted EBITDA of £11.3 million versus £15.8 million a year earlier.
  • US operations, mainly Soluna under the California state contract, generated £46.1 million of FY2025 revenue against £17.2 million from the UK; California alone represented 71% of group revenue.
  • Soluna passed 144,000 registered young people in California by end-2025, and Kooth secured a New Jersey renewal plus a new $2.6 million Michigan contract signed January 2026.
  • Kooth holds £21.6 million net cash and is debt-free, but free cash flow fell to £1.2 million in FY2025 from £10.2 million, and it has never paid a dividend.
  • Management guided 2026 revenue and adjusted EBITDA in line with market expectations, with a planned UK Soluna launch anticipated in H2 2026.

What Kooth Actually Does

Kooth designs and operates digital platforms giving children, young people and, increasingly, adults access to online counselling, moderated peer-support communities and self-help content. In the UK, its Kooth and Qwell services are commissioned by the NHS, local authorities and, more recently, the Department for Work and Pensions — what the company describes as NHS England's largest single access provider for youth mental health.

In the United States, Kooth trades as Soluna, delivering similar services under state and county behavioural-health contracts, most significantly with California's BrightLife Kids and CalHOPE youth initiatives, alongside newer relationships in New Jersey, Michigan and an Illinois Medicaid pilot. Because contracts follow public procurement, the customer base is concentrated among a small number of government commissioners, and essentially all revenue is recurring.

The 2025 Pause, Explained

For the year ended 31 December 2025, Kooth reported group revenue of £63.3 million, down from a record £66.7 million in FY2024, attributed to FX headwinds, lower California product-development fee income and Michigan mobilisation delays, partly offset by New Jersey revenue.

Adjusted EBITDA was £11.3 million, down from £15.8 million, while statutory operating profit fell to £3.4 million from £9.2 million. Free cash flow fell sharply to £1.2 million from £10.2 million, reflecting the lower earnings base and working-capital movements. Constant-currency net revenue retention was 96%, down from 100% — a signal that momentum, while still strong, isn't guaranteed.

Why California Matters So Much

US expansion is now the dominant growth engine, anchored by the California BrightLife Kids/CalHOPE programme delivered through Soluna, which had more than 144,000 registered young people and over 1,400 institutional partnerships by end-2025, plus a renewed New Jersey contract and a new $2.6 million Michigan agreement signed January 2026.

The flip side of that concentration: California alone represented 71% of group revenue in FY2025, down only marginally from 73%. Any material change to that relationship's scope, pricing or renewal terms would have an outsized effect on group financials.

UK Commissioning: A Softer Picture

NHS and UK public-sector contracts remain foundational: FY2025 saw 14 new UK contracts and a renewal-uplift rate of 54%, up from 45%, plus a new Department for Work and Pensions relationship. Even so, UK revenue slipped to £17.2 million from £18.0 million amid contract churn — a reminder that NHS and local-authority budget pressure can compress the domestic business even as the group grows overall.

A Debt-Free Balance Sheet — Reinvested, Not Distributed

Kooth ended FY2025 with £21.6 million of net cash and no debt, broadly stable against £21.8 million a year earlier, plus access to an undrawn $9.5 million working-capital facility. In the period the company completed a £1.5 million share buyback in February 2025, a modest return indicating comfort deploying spare cash.

Capitalised development costs of £4.4 million are the main ongoing investment need, funding AI-supported clinical tools. With no dividend competing for capital, free cash flow funds product development, US mobilisation and possible bolt-on acquisitions referenced at the 2026 AGM.

No Dividend, and No Plans for One

Kooth has not paid a dividend historically and did not recommend one for FY2025. The board intends to reinvest available cash for growth in the near to medium term, prioritising platform development, US contract mobilisation and potential selective acquisitions over cash distributions. Investors should treat Kooth as a capital-growth proposition rather than an income holding while this policy persists.

The Valuation Picture

With a share price of approximately 166.5p and roughly 36.9 million shares in issue, Kooth's market capitalisation is around £60.4 million, below FY2025 revenue of £63.3 million — implying a price-to-sales ratio of roughly 1x. Against FY2025 adjusted EBITDA of £11.3 million, the implied EV/EBITDA multiple is modest once £21.6 million net cash is netted off.

Risks Worth Weighing

The most concentrated risk facing Kooth is reliance on a single commissioning relationship: California represented 71% of group revenue in FY2025. UK revenue has also proven fragile, falling to £17.2 million amid contract churn. Currency exposure is a further factor, since most revenue is now dollar-denominated while the company reports in sterling. Free cash flow proved far more volatile than earnings, falling to £1.2 million from £10.2 million, a reminder that working-capital swings can strain cash generation despite the net cash balance sheet.

What to Watch Next

Watch progress on the planned UK launch of Soluna targeted for H2 2026, along with contract announcements or renewal updates from California, New Jersey, Michigan or other US states. The trajectory of net revenue retention, which slipped to 96% in FY2025, is a useful indicator of whether contracts renew on stable or improved terms.

Bottom Line

Kooth occupies a distinctive niche as a publicly-commissioned digital mental-health provider spanning the NHS in the UK and state-funded youth programmes in the US. The past year's decline in revenue and free cash flow, alongside a dip in net revenue retention, tempers what had been a period of rapid US-led growth, while heavy reliance on the California contract and softness in UK commissioning remain the central risks to monitor.